Senior U.S. House Democrat and Republican Say They’re Hopeful Congress Will Act on 340B; Hearings Expected in New Congress

Kelly and Guthrie
U.S. Reps. Robin Kelly (D-Ill.) and Brett Guthrie (R-Ky.) each said during an event yesterday they were hopeful Congress would act on 340B—Kelly regarding covered entities' concerns and Guthrie regarding those of payers and manufacturers.

The Democratic vice chair of the U.S. House Energy & Commerce Committee said during a media event yesterday she hopes Congress will address healthcare providers’ concerns about the 340B program during its lame duck session scheduled to end Dec. 15.

Read More »

Mike Braun, Key U.S. Senator on 340B Matters, Won’t See Re-Election in 2024

Mike Braun
U.S. Sen. Mike Braun (R-Ind.), a key voice on 340B matters, is running for governor of Indiana in 2024 instead of seeking re-election to Congress.

U.S. Sen. Mike Braun (R-Ind.), whom 340B covered entities have considered both a friend and foe, has decided to run for governor of Indiana in 2024 rather than seek reelection to the Senate.

Please

Read More »

AIDS Healthcare Foundation Criticizes Idea of Creating a 340C Program for Non-Hospital Providers

340C
AIDS Healthcare Foundation says taking non-hospital healthcare providers out of 340B and placing them in their own new 340C program is the wrong response to drug industry attacks on the existing program.

Separating the 340B drug discount program into one for hospitals and another for non-hospital healthcare providers would be the wrong response to drug company denials of 340B pricing when providers use contract pharmacies, AIDS Healthcare Foundation said yesterday.

Read More »

Local Community Group Continues Late Congressman’s Push for 340B Hospital Oversight

McEachin
U.S. Rep. A. Donald McEachin (D-Va.), who began an inquiry into alleged 340B program misuse involving a hospital in his district, died from complications of colorectal cancer Monday.

A Richmond, Va., citizen’s group is continuing the fight against a health system accused of 340B program misuse at a hospital in a low-income, majority Black neighborhood in the wake of the death of U.S. Rep. A. Donald

Read More »

With GOP Control of U.S. House, Expect Increased Oversight of 340B Providers

Kevin McCarthy
U.S. House GOP Leader Kevin McCarthy last night posted this tweet announcing his party will be the majority in the chamber for the next two years.

The Republican Party won control of the U.S. House last evening, securing the requisite 218th seat for majority status after the Associated Press declared Rep. Mike Garcia (R) the winner of a race in California.

Read More »

With Democrats Retaining Control of U.S. Senate, Expect New Leadership in Key Committee

Election
Democrats will still control the U.S. Senate for the next two years, but party control of the House had not yet been determined as of early this morning.

Democrats will still control the U.S. Senate for the next two years, it became clear over the weekend, but control of the House has not yet been decided one week after the Nov. 8 midterm elections.

Read More »

340B Law Should Be Amended to Include Emergency-Use COVID-19 Drugs, Health Affairs Opinion Article Says

Bebtelovimab
A screen shot from an HHS video about the monoclonal antibody betelovimab used to treat COVID-19 infection.

The 340B statute should be amended to extend discounts to emergency-use drugs to treat COVID-19 as a first step in rebuilding the COVID-19 safety net, an opinion piece published yesterday in the medical journal Health Affairs says.

Read More »

With Party Control of Congress Still Undecided, 340B Providers Lose Some Key Champions but Retain Some Heavy Hitters

Cathy McMorris Rodgers
Rep. Cathy McMorris Rodgers (R-Wash.) is in line to be the new House Energy & Commerce Committee chair if Republicans capture the majority in the still undecided midterm elections.

Partisan control of Congress for the final two years of President Biden’s term in office was still undecided this morning, two days after Tuesday’s mid-term elections.

Please Login or Become a Paid Subscriber to

Read More »

MedPAC Is Expected to Make a Policy Recommendation That Could Prompt a Look at 340B Hospital Program Eligibility Criteria

MedPAC
MedPAC is on track to make a recommendation to Congress that could prompt debate or even action on the 340B program’s use of the Medicare disproportionate share (DSH) patient percentage to determine hospital eligibility.

Congressional Medicare advisers are moving toward recommending what they say is a better way to give extra Medicare funding to safety-net hospitals that disproportionately serve low-income and/or uninsured beneficiaries.

Please Login or Become a

Read More »

As Interest in Legislation Grows, Congressional Research Service Issues Back-to-Back Reports on 340B Program

Congressional Research Service
The Congressional Research Service issued a four-page backgrounder on litigation over the 340B contract pharmacy program and a two-pager on the entire drug discount program.

Congress’ nonpartisan research office has issued a four-page backgrounder on litigation over the 340B contract pharmacy program and a two-pager on the entire drug discount program.

Please Login or Become a Paid Subscriber to

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report